Susan dosReis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8239386/publications.pdf

Version: 2024-02-01

79	2,571	23	49
papers	citations	h-index	g-index
81	81	81	2383
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Integrating the patient voice into pharmacoepidemiology research on the benefits and harms of medication. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 2963-2969.	0.8	1
2	Antipsychotic medications and admission to psychiatric residential treatment facilities among youth in foster care diagnosed with disruptive behavior disorders American Journal of Orthopsychiatry, 2022, 92, 474-482.	1.0	2
3	232 Psychotropic Medication Use Before Cancer Diagnosis Among US Adolescents and Young Adults. Journal of Clinical and Translational Science, 2022, 6, 37-37.	0.3	O
4	Trends in antipsychotic use for youth with attentionâ€deficit/hyperactivity disorder and disruptive behavior disorders. Pharmacoepidemiology and Drug Safety, 2022, , .	0.9	3
5	Characteristics of Youths Treated With Psychotropic Polypharmacy in the United States, 1999 to 2015. JAMA Pediatrics, 2021, 175, 196.	3.3	6
6	Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences. Patient, 2021, 14, 569-579.	1.1	5
7	Evaluation of Switchâ€toâ€Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Realâ€World Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2021, 110, 443-451.	2.3	2
8	Opioid prescribing and risks among commercially insured women undergoing pelvic organ prolapse repair. Pharmacoepidemiology and Drug Safety, 2021, 30, 993-1002.	0.9	2
9	Cardiovascular Risk of Concomitant Use of Atypical Antipsychotics and Stimulants Among Commercially Insured Youth in the United States. Frontiers in Psychiatry, 2021, 12, 640244.	1.3	3
10	Evaluating the association between antidepressant dose trajectories and treatment augmentation in pediatric depression. Pharmacoepidemiology and Drug Safety, 2021, , .	0.9	1
11	Community Adversity and Utilization of Psychotropic Medications Among Children in Foster Care. Journal of Behavioral Health Services and Research, 2021, , 1.	0.6	1
12	Care Management for Youth With Comorbid Developmental and Mental Health Conditions: A Discrete Choice Experiment Pilot Study. Academic Pediatrics, 2020, 20, 241-249.	1.0	2
13	Stakeholder-Engaged Derivation of Patient-Informed Value Elements. Patient, 2020, 13, 611-621.	1.1	18
14	The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment. Patient, 2020, 14, 381-384.	1.1	5
15	Family Adverse Experiences and Psychotropic Polypharmacy Among US Youth: 2009–2015. Pediatrics, 2020, 145, .	1.0	6
16	Spillover effects of state medicaid antipsychotic prior authorization policies in <scp>US commercially insured</scp> youth. Pharmacoepidemiology and Drug Safety, 2020, 29, 1064-1071.	0.9	4
17	Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case. Value in Health, 2019, 22, 545-548.	0.1	15
18	Psychiatric Services Preceding Initiation of Antipsychotic Medication Among Youth in Foster Care. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 276-284.	0.7	1

#	Article	IF	CITATIONS
19	Engaging stakeholders in pharmacoepidemiology research: Current state and recommendations. Pharmacoepidemiology and Drug Safety, 2019, 28, 766-776.	0.9	10
20	Best-Worst Scaling to Prioritize Outcomes Meaningful to Caregivers of Youth with Mental Health Multimorbidities: A Pilot Study. Journal of Developmental and Behavioral Pediatrics, 2018, 39, 101-108.	0.6	6
21	Caregivers' Priorities and Observed Outcomes of Attention-Deficit Hyperactivity Disorder Medication for Their Children. Journal of Developmental and Behavioral Pediatrics, 2018, 39, 93-100.	0.6	5
22	Engaging Caregivers in the Treatment of Youth with Complex Developmental and Mental Health Needs. Journal of Behavioral Health Services and Research, 2018, 45, 440-453.	0.6	6
23	Psychotropic Polypharmacy Among Youths With Serious Emotional and Behavioral Disorders Receiving Coordinated Care Services. Psychiatric Services, 2018, 69, 716-722.	1.1	15
24	Emerging Good Practices for Transforming Value Assessment: Patients' Voices, Patients' Values. Value in Health, 2018, 21, 386-393.	0.1	12
25	College students' perceived benefit-to-risk tradeoffs for nonmedical use of prescription stimulants: Implications for intervention designs. Addictive Behaviors, 2018, 79, 45-51.	1.7	13
26	Impact of Coordinated Behavioral Health Management on Quality Measures of Antipsychotic Use. Administration and Policy in Mental Health and Mental Health Services Research, 2018, 45, 174-185.	1.2	7
27	Impact of a Care Management Entity on Use of Psychiatric Services Among Youths With Severe Mental or Behavioral Disorders. Psychiatric Services, 2018, 69, 1167-1174.	1.1	4
28	Cardiovascular Events Following Treatment Initiation with Atypical Antipsychotic Medications in Publicly Insured U.S. Youth. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 445-453.	0.7	5
29	Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients. Medical Care, 2017, 55, e104-e112.	1.1	12
30	<scp>ADHD</scp> medications and cardiovascular adverse events in children and adolescents: crossâ€national comparison of risk communication in drug labeling. Pharmacoepidemiology and Drug Safety, 2017, 26, 274-284.	0.9	5
31	A Latent Class Analysis to Identify Variation in Caregivers' Preferences for their Child's Attention-Deficit/Hyperactivity Disorder Treatment: Do Stated Preferences Match Current Treatment?. Patient, 2017, 10, 251-262.	1.1	17
32	Caregiver Treatment Preferences for Children with a New Versus Existing Attention-Deficit/Hyperactivity Disorder Diagnosis. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 234-242.	0.7	17
33	[P2–503]: CARE MANAGEMENT PREFERENCES FOR INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT (MCI). Alzheimer's and Dementia, 2017, 13, P834.	0.4	0
34	Research is needed on the difficultâ€toâ€cure population of hepatitis C virus patients with disability. Hepatology, 2016, 63, 2067-2068.	3.6	0
35	P4â€247: Integrating Clinical and Qualityâ€Ofâ€Life Scales in Care Management Preferences for Individuals With Mild Cognitive Impairment (MCI). Alzheimer's and Dementia, 2016, 12, P1125.	0.4	0
36	P4â€370: Eliciting Care Plan and Treatment Goals for Caregivers of Individuals with Alzheimer's Disease and Related Dementias: a Survey Pilot. Alzheimer's and Dementia, 2016, 12, P1179.	0.4	0

#	Article	IF	CITATIONS
37	Attribute Development Using Continuous Stakeholder Engagement to Prioritize Treatment Decisions: A Framework for Patient-Centered Research. Value in Health, 2016, 19, 758-766.	0.1	22
38	Antipsychotic Use and Foster Care Placement Stability Among Youth With Attention-Deficit Hyperactivity/ Disruptive Behavior Disorders. Journal of Public Child Welfare, 2016, 10, 376-390.	0.6	3
39	A National Survey of State Medicaid Psychotropic-Monitoring Programs Targeting Youths. Psychiatric Services, 2016, 67, 1146-1148.	1.1	9
40	A Best-Worst Scaling Experiment to Prioritize Caregiver Concerns About ADHD Medication for Children. Psychiatric Services, 2015, 66, 208-211.	1.1	23
41	Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1447-1462.	1.4	1
42	Systematic Review of Patients' and Parents' Preferences for ADHD Treatment Options and Processes of Care. Patient, 2015, 8, 483-497.	1.1	53
43	Using Best–Worst Scaling to Measure Caregiver Preferences for Managing their Child's ADHD: A Pilot Study. Patient, 2015, 8, 423-431.	1.1	19
44	Age-Related Trends in Psychotropic Medication Use Among Very Young Children in Foster Care. Psychiatric Services, 2014, 65, 1452-1457.	1.1	24
45	A Phenomenological Case Study of Communication Between Clinicians About Attention-Deficit/Hyperactivity Disorder Assessment. Clinical Pediatrics, 2014, 53, 11-17.	0.4	4
46	Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 960-970.e2.	0.3	53
47	Digging for data on harms in duloxetine trials. BMJ, The, 2014, 348, g3578-g3578.	3.0	3
48	Antipsychotic Treatment Patterns and Aggressive Behavior Among Adolescents in Residential Facilities. Journal of Behavioral Health Services and Research, 2013, 40, 97-110.	0.6	12
49	The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 264-278.e2.	0.3	162
50	Engaging hard-to-reach patients in patient-centered outcomes research. Journal of Comparative Effectiveness Research, 2013, 2, 313-324.	0.6	47
51	Characteristics of Patients With Histories of Multiple Seclusion and Restraint Events During a Single Psychiatric Hospitalization. Journal of the American Psychiatric Nurses Association, 2012, 18, 159-165.	0.4	20
52	The Relationship between Mental Health Diagnosis and Treatment with Secondâ€Generation Antipsychotics over Time: A National Study of <scp>U.S.</scp> Medicaidâ€Enrolled Children. Health Services Research, 2012, 47, 1836-1860.	1.0	78
53	Interstate variation in trends of psychotropic medication use among Medicaid-enrolled children in foster care. Children and Youth Services Review, 2012, 34, 1492-1499.	1.0	65
54	Is serious mental illness associated with earlier death among persons with human immunodeficiency virus (HIV)? A ten year follow up in Maryland Medicaid recipients. Journal of AIDS and HIV Research (Online), 2012, 4, 213-218.	0.4	3

#	Article	IF	CITATIONS
55	Connections to Outpatient Mental Health Care of Youths With Repeat Emergency Department Visits for Psychiatric Crises. Psychiatric Services, 2011, 62, 646-649.	1.1	45
56	Influence of Caregivers' Experiences on Service Use Among Children With Attention-Deficit Hyperactivity Disorder. Psychiatric Services, 2011, 62, 734-739.	1.1	11
57	Antipsychotic Treatment Among Youth in Foster Care. Pediatrics, 2011, 128, e1459-e1466.	1.0	89
58	Complexity and Continuity of Treatments Among Privately Insured Youth Diagnosed with Bipolar Disorder. Frontiers in Psychiatry, 2010, 1, 144.	1.3	4
59	Early Identification of Seclusion and Restraint Patterns During Adolescents' Course of Residential Treatment for Children and Youth, 2010, 27, 160-174.	0.6	20
60	Stigmatizing Experiences of Parents of Children With a New Diagnosis of ADHD. Psychiatric Services, 2010, 61, 811-816.	1,1	109
61	Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 119-126.	0.7	66
62	The Meaning of Attention-Deficit/Hyperactivity Disorder Medication and Parents' Initiation and Continuity of Treatment for Their Child. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 377-383.	0.7	75
63	Identifying patient-relevant endpoints among individuals with schizophrenia: An application of patient-centered health technology assessment. International Journal of Technology Assessment in Health Care, 2009, 25, 35-41.	0.2	45
64	Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. Schizophrenia Research, 2008, 101, 304-311.	1.1	20
65	Staff Perspectives of Precipitants to Aggressive Behavior of Adolescents in Residential Treatment Facilities. Residential Treatment for Children and Youth, 2008, 25, 85-101.	0.6	4
66	Parental attitudes and involvement in psychopharmacological treatment for ADHD: A conceptual model. International Review of Psychiatry, 2008, 20, 135-141.	1.4	41
67	African American caretakers' views of ADHD and use of outpatient mental health care services for children Families, Systems and Health, 2008, 26, 447-458.	0.4	15
68	Dialogues on Mixed-Methods and Mental Health Services Research: Anticipating Challenges, Building Solutions. Psychiatric Services, 2008, 59, 727-731.	1.1	37
69	Coming to Terms With ADHD: How Urban African-American Families Come to Seek Care for Their Children. Psychiatric Services, 2007, 58, 636-641.	1.1	51
70	Autism Spectrum Disorder Screening and Management Practices Among General Pediatric Providers. Journal of Developmental and Behavioral Pediatrics, 2006, 27, S88-S94.	0.6	171
71	Attitudes About Stimulant Medication for Attention-Deficit/Hyperactivity Disorder Among African American Families in an Inner City Community. Journal of Behavioral Health Services and Research, 2006, 33, 423-430.	0.6	43
72	Multimodal Treatment for ADHD Among Youths in Three Medicaid Subgroups: Disabled, Foster Care, and Low Income. Psychiatric Services, 2004, 55, 1041-1048.	1.1	19

SUSAN DOSREIS

#	Article	IF	CITATION
73	Psychotropic Practice Patterns for Youth. JAMA Pediatrics, 2003, 157, 17.	3.6	470
74	A Guide for Managing Acute Aggressive Behavior of Youths in Residential and Inpatient Treatment Facilities. Psychiatric Services, 2003, 54, 1357-1363.	1.1	33
75	Parental Perceptions and Satisfaction with Stimulant Medication for Attention-Deficit Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics, 2003, 24, 155-162.	0.6	182
76	Concomitant Psychotropic Medication for Youths. American Journal of Psychiatry, 2003, 160, 438-449.	4.0	143
77	Antipsychotic Dosing and Concurrent Psychotropic Treatments for Medicaid-Insured Individuals With Schizophrenia. Schizophrenia Bulletin, 2002, 28, 607-617.	2.3	24
78	Improving the Management of Acute Aggression in State Residential and Inpatient Psychiatric Facilities for Youths. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 897-905.	0.3	30
79	Title is missing!. Journal of Child and Family Studies, 2001, 10, 385-397.	0.7	10